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DOI 10.1186/s13075-016-0978-1RESEARCH ARTICLE Open AccessRegulatory and effector B cell cytokine
production in patients with relapsing
granulomatosis with polyangiitis
Judith Land1, Wayel H. Abdulahad1, Jan-Stephan F. Sanders2, Coen A. Stegeman2, Peter Heeringa3
and Abraham Rutgers1*Abstract
Background: B cells are capable of producing regulatory and effector cytokines. In patients with granulomatosis
with polyangiitis (GPA), skewing of the pro- and anti-inflammatory cytokine balance may affect the risk of relapse.
This study aimed to investigate differences in B cell cytokine production in patients with relapsing GPA and in
controls, and determine whether this can aid in relapse prediction.
Methods: Thirteen GPA patients with an upcoming relapse were matched with non-relapsing patients and healthy
controls in a retrospective design. The B cell subset distribution was determined from peripheral blood.
Cryopreserved peripheral blood mononuclear cells were cultured and intracellular B cell production of regulatory
(IL10) and effector (TNFα, IFNγ, IL2, IL6) cytokines was assessed. Finally, serum markers associated with B cell
activation (sCD27) and migration (CCL19) were determined.
Results: GPA patient samples exhibited significantly lower percentages of TNFα+ B cells than controls, an effect that
was most pronounced in patients about to relapse. B cell capacity for IL10 production was similar in patients and
controls. No significant differences were observed for cytokine production in relapsing and non-relapsing GPA patients.
TNFα production correlated strongly with IL2, IFNγ and the percentage of memory B cells. No change in effector
cytokines occurred before relapse, while the percentage of IL10+ B cells significantly decreased. GPA patients in
remission had increased serum levels of CCL19 and sCD27, and sCD27 levels increased upon active disease.
Conclusions: While differences in effector B cell cytokine production were observed between patients and controls,
monitoring this in GPA did not clearly distinguish patients about to relapse. Prospective measurements of the
regulatory cytokine IL10 may have potential for relapse prediction. Memory B cells appear mainly responsible for
effector cytokine production. Increased migration of these cells could explain the decreased presence of TNFα+ B cells
in the circulation.
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Anti-neutrophil cytoplasmic antibodies (ANCA) are
associated with chronic inflammatory small vessel
vasculitides such as granulomatosis with polyangiitis
(GPA). Patients with GPA frequently have circulating
autoantibodies directed against the neutrophil constituent* Correspondence: a.rutgers@umcg.nl
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while numerous risk factors for relapse have been
described, no good markers are available to predict
upcoming relapses in individual patients [2, 3]. B cells are
important effector cells in autoimmune disease pathogen-
esis, not only as the producers of autoantibodies, but also
as antigen presenting cells and cytokine producers [4]. B
cell depletion therapy using the anti-CD20 monoclonal
antibody rituximab has proven to be an effective
therapeutic strategy for inducing remission in GPA [5, 6],
indicating a pathogenic role for these cells. Clinicaldistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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the reduction in autoantibody titers [7], highlighting the
importance of antibody-independent mechanisms of B
cells. Moreover, a subset of B cells has been ascribed with
regulatory functions through the production of anti-
inflammatory cytokines like interleukin (IL)10 [8].
These cells have been termed regulatory B cells (Breg)
but there is no commonly accepted phenotypical
description for this subset. It has been proposed that
Bregs could be identified in the circulation by their
surface markers, including CD24highCD38high [9],
CD24highCD27+ [10] and CD5+ B cells [11], although
Bregs are functionally defined as IL10-producing B
cells. Several studies have examined IL10 production
in patients with ANCA-associated vasculitis (AAV).
The results are inconclusive, as in one study patients
with active AAV had lower production of IL10 [12],
in another there was decreased IL10 production in pa-
tients with active disease and in patients in remission [13],
while in a third study there were no differences compared
to healthy controls [14]. None of these studies examined
whether IL10 production changes in individual patients
prior to relapse, or investigated production of other
cytokines. This may be relevant because B cells are also
capable of producing proinflammatory cytokines [15].
For these effector B cells (Beff ) numerous effects on
the immune response have been described in mouse
models [16]. Tumor necrosis factor (TNF) expressed by
B cells promotes T-helper 1 (Th1) differentiation, lead-
ing to amplification of interferon (IFN)γ production by
CD4+ and CD8+ T cells [17]. IFNγ produced by B cells
could also support Th1 responses [18], and promote
macrophage activation [19]. B cells can promote Th2
memory responses through production of IL2 [20] and
produce large quantities of IL6, shown capable of
increasing disease pathogenesis in experimental auto-
immune encephalomyelitis models through activation of
Th17 cells [7]. Moreover, several cytokines, including
IL6 and TNFα, can support the survival of plasma cells
[21]. Collectively, these observations indicate that cyto-
kine production by B cells might be an important factor
in autoimmune disease pathogenesis. In patients with
GPA the Breg and Beff cytokine production may be a
factor that affects the balance between remission and
relapse. However, data on human B cell cytokine pro-
duction in autoimmunity are scarce. In the present study
we investigated whether production of proinflammatory
and anti-inflammatory cytokines by B cells in patients
with GPA deviates from that in healthy individuals and
examined whether analysis of the B cell cytokine
production profile could help predict upcoming relapses.
As B cell cytokine production from peripheral cells may
be affected by B cell migration and activation, markers
for these processes were also assessed.Methods
Study population
A cohort of 84 patients with PR3-ANCA-positive GPA was
prospectively monitored for 15–24 months. Clinical
parameters, including current therapy, were recorded and
peripheral blood mononuclear cells (PBMC) and serum
samples were stored. Sixteen patients relapsed during the
period of sample collection. Relapses were based on clinical
judgement and had to result in the decision to increase or
initiate immunosuppressive therapy. From the patients
who went on to have a future relapse, a retrospective selec-
tion was made based on availability of PBMC and the pres-
ence of more than 3 % of B cells within the lymphocyte
population. This resulted in a selection of 13 patients, who
were individually age- and sex-matched with 13 patients
with GPA, who did not relapse for at least 1.5 years and 13
healthy controls, prior to data analysis. The median time be-
tween sampling and relapse was 74 (range 14–157) days.
Samples from an earlier time point in remission were also
available for 11 patients who relapsed, and the median time
between the two samples prior to relapse was 98 (range
38–140) days. The diagnosis of GPA was based on defini-
tions outlined in the Chapel Hill Consensus Conference [22]
and all patients fulfilled the classification criteria of the
American College of Rheumatology [23]. All subjects gave
written informed consent according to the Declaration of
Helsinki and the study was approved by the Medical Ethical
Committee of the University Medical Center Groningen
(METc UMCG 2012/151). Patient and control characteristics
are listed in Table 1. Clinical data of the individual patients
at time of relapse is listed in Additional file 1 : Table S1.
Flow cytometry for analysis of the B cell phenotype
Blood was collected in EDTA tubes, and 100 μl was incu-
bated with anti-human CD19-eFluor450 (eBioscience, San
Diego, CA, USA), CD24-fluorescein isothiocyanate (FITC)
(BD biosciences, Franklin Lakes, NJ, USA), CD27-APC-
eFluor780 (eBioscience), CD38-PeCy5 (eBioscience), CD5-
PerCp-Cy5.5 (Biolegend, San Diego, CA, USA) or the
corresponding isotype controls. After 15 minutes cells were
treated with fluorescence-activated cell sorting (FACS)
Lysing solution (BD Biosciences). Samples were measured
using an LSR-II flow cytometer (BD biosciences) and data
were analyzed using Kaluza 1.2 flow analysis software
(Beckman Coulter, Brea, CA, USA). B cells were divided
into transitional, memory, naive, CD24highCD38high and
CD24highCD27+ B cells as described previously [14]. CD5+
B cells were gated on an isotype control.
Cell culture and intracellular B cell cytokine pattern upon
in vitro stimulation
PBMC were isolated and stored in RPMI 1640 (Lonzo,
Basel, Switzerland) supplemented with 50 μg/mL genta-
mycin (GIBCO, Life Technologies, Grand Island, NY,
Table 1 Characteristics of patients with GPA and healthy controls
HC GPA, no future relapse GPA, future relapse
Subjects, n (% male) 13 (46) 13 (46) 13 (46)
Age, years, mean (range) 55 (44–74) 52 (32–76) 52 (32–75)
PR3-ANCA titer, median (range) 1:40 (0 to >640) 1:80 (20 to >640)
Disease duration, years, median (range) 12.6 (5.5–31.5) 15.3 (2.3–24.3)
Number of previous relapses, median (range) 2 (0–5) 5 (1–10)
Time to relapse after sample, days, median (range) n/a 74 (14–157)
Disease form, n (%)
Localized 0 (0) 0 (0)
Early systemic 2 (15.4) 2 (15.4)
Generalized 8 (61.5) 9 (69.2)
Severe 3 (23.1) 2 (15.4)
Treatment at time of sampling, n (%)
Aza 1 (7.7) 3 (23.1)
Pred 1 (7.7) 1 (7.7)
MMF + pred 2 (15.4) 3 (23.1)
No immunosuppressive therapy 9 (69.2) 6 (46.2)
B cell phenotype in %, median (range)
Total CD19+ B cells 12.3 (6.6–22.24) 9.8 (6.3–28.6) 9.9 (3.4–19.9)
Transitional B cells 10.77 (3.9–17.6) 9.2 (4.8–18.1) 9.3 (3.1–11.7)
Naive B cells 63.6 (37.4–83.4) 79.0 (74.5–90.1) 79.3 (60.1–85.7)
Memory B cells 22.4 (6.6–54.0) 8.1 (4.2–29.7) 8.2 (2.3–19.5)
CD24highCD38high B cells 6.6 (2.2–9.6) 4.6 (2.1–11.8) 5.3 (0.9–8.5)
CD24highCD27+ B cells 15.5 (3.5–45.4) 3.3 (2.1–24.8) 3.4 (0.7–10.8)
CD5+ B cells 23.4 (12.1–57.6) 19.8 (12.1–64.2) 18.9 (4.7–49.9)
ANCA anti-neutrophil cytoplasmic antibody, Aza azathioprine, GPA granulomatosis with polyangiitis, HC healthy controls, MMF mycophenolate mofetil, n/a not ap-
plicable, PR3 proteinase-3, Pred prednisolone
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dimethyl sulfoxide. The cryopreserved PBMC were
thawed, concentrations were adjusted to 106 cells/mL in
RPMI + 10 % FCS, and cells were seeded in 24-well flat
bottom plates (Corning, NY, USA). Cells were left
untreated or stimulated using 500 ng/mL CpG-
oligodeoxynucleotides (ODN) 2006 (Hycult Biotech,
Uden, the Netherlands). Culture plates were incubated
for 72 h at 37 °C with 5 % CO2. During the last 5 h of
incubation 50 ng/mL phorbol myristate acetate (PMA;
Sigma-Aldrich, St Louis, MO, USA), 2 mM calcium
ionophore (CaI; Sigma-Aldrich) and/or 10 μg/mL
Brefeldin A (BFA; Sigma-Aldrich) were added to the cell
culture. Cells were harvested and stained using anti-
human CD19-eFluor450 and CD22-PeCy5 (Biolegend).
Subsequently cells were fixed and permeabilized for
intracellular staining using a Fix&Perm kit (Invitrogen,
Life Technologies, Grand Island, NY, USA) and
incubated with antibodies against human IL10-PE
(Biolegend), TNFα-Alexa Fluor 488 (BD biosciences),
IL6-APC (eBioscience), IL2-PeCy7 (eBioscience) andIFNγ-Alexa Fluor 700 (BD biosciences). Samples were
measured with an LSR-II flow cytometer and data were
analyzed using Kaluza 1.2. Samples that had not been
stimulated with PMA and CaI were used as negative
controls to set the gates during data analysis. Data are
presented as the percentage of cytokine-positive B cells
within the total CD19+CD22+ population.
Enzyme-linked immunosorbent assay (ELISA) for CCL19
and soluble CD27
Serum samples from healthy controls and patients had
been collected and stored at −80 °C on the same day as
PBMC storage and B cell phenotype analysis. Moreover,
serum samples from the relapsing patients were available
from the time of active disease. A Human CCL19/MIP-3
beta DuoSet ELISA (R&D Systems, Minneapolis, MN,
USA) and a PeliKine Compact™ human soluble CD27
ELISA (Sanquin, Amsterdam, the Netherlands) were
performed according to the manufacturers’ instructions.
CCL19 levels are expressed as pg/mL and sCD27 levels
as units (U)/mL.
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Statistical analysis was performed using SPSS v22 (IBM
Corporation, Chicago, IL, USA) and GraphPad Prism
v5.0 (GraphPad Software, San Diego, CA, USA). Data
are presented as median values with the interquartile
range, unless stated otherwise. For comparison between
groups the unpaired t test was applied for data with a
Gaussian distribution and the Mann-Whitney U test was
used for data with a non-Gaussian distribution. For
intra-individual comparisons the paired t test or
Wilcoxon matched pairs test was performed for
Gaussian- and non-Gaussian-distributed data, respect-
ively. Correlation analysis was performed by calculating
the Spearman rank correlation coefficient. P values <0.05
were considered statistically significant.
Results
B cell subset distribution in patients with GPA and
healthy controls
The B cell subset distribution in patients with GPA in
remission differed from healthy controls (HC). Specif-
ically, patients with GPA had lower percentages of
CD27+ memory B cells (p = 0.0014), CD24highCD27+
B cells (p < 0.001) and higher percentages of naive B
cells (p < 0.001) than healthy controls (Table 1). These
same differences were observed when patients who
were on immunosuppressive treatment at that time
were excluded from analysis. No significant differ-
ences were found when directly comparing patients
who did or did not have a future relapse.
Intracellular B cell cytokine pattern in patients with GPA
and healthy controls
PBMC were cultured with or without CpG for 3 days,
followed by PMA and CaI stimulation for 5 h. In all
samples the production of TNFα, IL2, IFNγ, IL6 and
IL10 was determined by flow cytometry (Fig. 1). IL10
production was only clearly detectable when samples
had been stimulated with CpG; without CpG IL10 was
detected in less than 0.5 % of B cells. In contrast, for the
effector cytokines there were clear positive populations
both with and without CpG stimulation. Simultaneous
production of regulatory and effector cytokines was also
observed in B cells. For example, the median double
positivity for IL10 and TNFα was 20 % of the total IL10-
positive B cell population; this proportion was similar
for patients with GPA and controls. Moreover, the Beff
cytokines IL2, IFNγ and TNFα were regularly produced
together by B cells.
First, all GPA patients in remission were compared to
the healthy controls. In samples not incubated with CpG
a lower percentage of TNFα-producing B cells was
present in samples from patients with GPA (median
7.3 %, interquartile range 5.5–10.0 %) compared tohealthy controls (12.3, 8.7–18.8 %, p = 0.003). Expression
of the other cytokines was not significantly different
between controls and patients, although numerically the
percentages of B cells positive for IL2 (6.7, 4.7–8.2 % in
HC vs 5.1, 2.7–6.8 % in GPA) and IFNγ (6.0, 3.8–6.7 %
vs 4.2, 3.3–4.9 %) were lower in patients, while IL6 (21.2,
15.6–26.3 % vs 26.2, 20.9–31.1 %) appeared mildly
increased in GPA. In samples stimulated with CpG no
significant differences were observed for B cell produc-
tion of IL10 between healthy controls (6.7, 3.8–9.7 %)
and patients with GPA (6.5, 3.6–9.6 %), or for the ef-
fector cytokines (data not shown). Stimulation with CpG
also affected the production of IL6, by inducing a signifi-
cant increase in IL6+ B cells in both patient and control
samples (p = 0.0014). Furthermore, a significant decrease
in TNFα+ B cells was seen upon CpG stimulation in
healthy control samples (p = 0.017), whereas in patients
there was a more diverse response. The results for samples
not stimulated with CpG were used for the remaining
analyses, with the exception of IL10.Changes in B cell cytokine production before relapse
The patients with GPA in remission were divided into
those who were diagnosed with a relapse after sampling
and those who had not relapsed for at least 1.5 years
after sampling. These groups were compared with each
other and with the HC. There were no significant differ-
ences in production of the regulatory cytokine IL10
between the patient groups and the HC. The differences
we observed in the effector cytokine production for
patients with GPA and controls were most notable in
the patients who had relapsed after sampling (Fig. 2).
There were fewer TNFα+ B cells in the samples from
non-relapsing patients (7.9, 5.5–10.0 %, p = 0.045) com-
pared to the control samples, but when comparing relaps-
ing patients (6.7, 4.6–8.0 %, p = 0.002) to controls this
difference appeared to be more pronounced. Relapsing
patients also appeared to have fewer IL2+ B cells
than controls, albeit not significantly so (3.6, 2.3–
7.2 %, p = 0.058). This was the same for the increased
proportion of IL6+ B cells in relapsing patients (27.7,
20.9–35.9 %, p = 0.10) compared to HC. However, when
compared directly, there was no significant difference in
the production of any cytokine in the relapsing and non-
relapsing patients.
Two consecutive samples before relapse were available
for 11 patients, and changes in cytokine production were
analyzed. No clear change in the production of effector
cytokines occurred prior to relapse (Fig. 3a-d), while
there was a significant decrease in IL10+ B cells (Fig. 3e).
In eight patients in sustained remission, no significant
change was observed in the production of IL10 between
two consecutive samples (Additional file 1: Figure S1).
Fig. 1 Flow cytometry gating example. Representative flow cytometry dot plots of CD19+CD22+ B cells. a Brefeldin A (BFA)-treated samples.
b Phorbol myristate acetate (PMA)- and calcium ionophore (CaI)-stimulated, BFA-treated samples. c CpG-oligodeoxynucleotide (CpG-ODN)-stimulated,
BFA-treated samples. d CpG-ODN-, PMA-, and CaI-stimulated, BFA-treated samples. To determine the percentage of B cells positive for cytokine
production (a) and (c) were used as negative controls to set the gates for (b) and (d), respectively
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patients in the relapse and non-relapse groups (albeit not
significant) we compared all patients who were currently
on immunosuppressive treatment (n = 11) to those who
were not (n = 15). The percentages of TNFα-, IL2-, and
IFNγ-producing cells were significantly higher in patients
who were currently being treated (Fig. 4a-c); as more
patients were treated in the relapse group this is unlikely
to have affected the significance of our results. IL10 andIL6 production was not significantly different in treated
and untreated patients (Fig. 4d-e).
Correlation analysis for the B cell phenotype and
cytokine production
The results from the correlation analysis for the B cell
subset distribution and B cell cytokine production are
summarized in Table 2. Results are from the combined
cohorts of patients with GPA (n = 26) and healthy
Fig. 2 B cell cytokine production in (relapsing) patients with granulomatosis with polyangiitis (GPA) and in controls. Peripheral blood mononuclear
cells were cultured without CpG-oligodeoxynucleotides (CpG-ODN) (a-d) and with CpG-ODN (e). Total percentages of cytokine-producing B cells were
determined within the CD19+CD22+ B cell population. Patients were divided into those who relapsed soon after the sampling (future relapse) and
those that did not relapse for at least 1.5 years (no future relapse). Graphs represent data from 13 relapsing patients, 13 non-relapsing patients and 13
healthy controls. In the box and whisker plots (Tukey), boxes represent median values and the interquartile range: *p < 0.05, **p < 0.01
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the effector cytokines TNFα, IL2 and IFNγ. Production
of these cytokines, in particular TNFα, also demon-
strated a strong positive correlation with the percentage
of circulating CD27+ memory B cells. These results were
also observed when patients 10.1186/s13075-016-0978-1
correlation with the percentage of circulating CD27+
memory B cells. These results were also observed when
patients with GPA were analyzed separately. There was
positive correlation with the production of IL6 and IL10
in CpG-stimulated samples. There was no correlation
between these cytokines and any specific B cell subset.
Interestingly, there was no correlation between the pro-
duction of IL10 and any of the proposed Breg populations.CCL19 and sCD27 serum levels are increased in patients
with GPA
As results were obtained using peripheral blood cells,
differences in B cell migration and activation were inves-
tigated by analyzing the B cell trafficking chemokine
CCL19 [24, 25] and soluble CD27 serum levels, using
ELISA. CCL19 was significantly increased in patients
with GPA in remission (144, 105–281 pg/mL) compared
to healthy controls (102, 81–131; Fig. 5a). When patients
in remission were divided based on future relapse, no
significant difference was observed in CCL19 serum levels
between patients who did (153, 99–402) and did not (142,
105–187) relapse after sampling (Fig. 5c). CCL19 levels in
relapsing patients did not change between the two time
points before the relapse, or upon active disease (Fig. 5e).There was no correlation between serum levels of CCL19
and the B cell phenotype distribution.
Serum levels of sCD27 were significantly increased in
patients in remission (255, 216–337 U/mL) and patients
with active disease (319, 259–418) compared to healthy
controls (221, 210–251; Fig. 5b). Concentrations were
not different when patients were divided into those with
(261, 227–360) and without (255, 213–407) an upcom-
ing relapse (Fig. 5d). While no clear change in sCD27
levels occurred prior to relapse, when patients presented
with active disease, there was a significant increase in
sCD27 (median 21 %) (Fig. 5f ). There was no correlation
between sCD27 serum levels and the percentage of
circulating CD27+ memory cells, or other B cell subsets
in remission patients or controls.
Discussion
The antibody-independent functions of B cells are of
increasing interest. This includes the production of both
proinflammatory and anti-inflammatory cytokines. In
particular, the production of IL10 and the presence of
Bregs in autoimmune disease are currently under investi-
gation. Scant information is available about B cell
cytokine production in patients with GPA, especially Beff
cytokine production, and how this may relate to an
upcoming relapse. Here we describe the B cell cytokine
production profile in patients with GPA in remission,
patients about to relapse, and matched healthy controls.
The most prominent result of this analysis is that
patients with GPA had a significantly lower percentage
of TNFα-producing B cells in the circulation, and this
Fig. 3 Changes in B cell cytokine production before relapse. For 11 relapsing patients two consecutive time points before relapse were analyzed
simultaneously, to determine whether changes in cytokine production occurred prior to relapse. Peripheral blood mononuclear cells were cultured
without CpG-oligodeoxynucleotides (CpG-ODN) (a-d) and with CpG-ODN (e). Total percentages of cytokine-producing B cells were determined within
the CD19+CD22+ B cell population. Graphs represent data from 11 patients and each connected line represents an individual patient. The different
symbols indicate the individual patients in each subgraph. R-1 indicates the sample taken closest to relapse and R-2 the sample taken before. *P < 0.05
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lapse. TNFα-producing B cells correlated very strongly
with the presence of CD27+ memory B cells in the
circulation. We observed that patients with GPA had a
decreased proportion of CD27+ memory B cells in
peripheral blood, confirming our previously described
results [14]. Moreover, we have found that CD27+ mem-
ory B cells are even further decreased in patients prior
to relapse (unpublished data). CD27+ memory B cells
have a greater capacity to produce TNFα than naive B
cells in patients with rheumatoid arthritis (RA) [26]. It is
likely that the reduced proportion of CD27+ memory
cells in patients with GPA [14] explains the lower per-
centage of TNFα-producing cells in our study. Both IL2
and IFNγ production correlated strongly with the pro-
duction of TNFα and the percentage of CD27+ memory
B cells, suggesting that effector B cells produce several
proinflammatory cytokines simultaneously.One potential explanation for the decreased presence
of TNFα-producing CD27+ memory B cells in the circu-
lation is a higher rate of B cell trafficking in GPA, which
mainly affects the memory B cells. As a first attempt to
investigate this option the B cell trafficking chemokine
CCL19 was measured in serum samples. CCL19 has
been described to especially enhance the migration of
CD27+ memory B cells [25]. Levels of CCL19 were
indeed increased in patients with GPA compared to
controls, suggesting that B cell migration is intensified
in these patients. In patients with RA the level of serum
CCL19 has been weakly and inversely correlated with
the frequency of circulating CD27+ memory B cells [27]
and increased levels of CCL19 have been found in
synovial tissue [28]. Moreover, CCL19 is involved in the
formation of ectopic lymphoid structures [24]. We did
not observe correlation between CCL19 and the percent-
age of CD27+ cells in the GPA cohort or in the healthy
Fig. 4 Current medication use and B cell cytokine production. a-e All patients with granulomatosis with polyangiitis (GPA) were divided into groups
based on whether they were receiving immunosuppressive treatment at the time of sampling. Graphs represent data for 11 patients who were treated
at the time of sampling and 15 who were not treated. In the box and whisker plots (Tukey), the boxes represent median values and the interquartile
range. *P < 0.05
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the correlation coefficient was not high, and the number
of subjects in our study is substantially lower. Increased
migration of CD27+ memory B cells is a viable option to
explain their decreased proportion in the circulation of
patients with GPA. Investigation of tissue biopsies is
warranted to prove that. Concentrations of CCL19 did
not change before or at the time of relapse, indicating
that CCL19 cannot differentiate between patients withTable 2 Correlation analysis results
TNFα+, %
Memory, % Spearman’s rho 0.864*
P value <0.0001*
CD24highCD38high, % Spearman’s rho -0.237
P value 0.146
CD24highCD27+, % Spearman’s rho 0.834*
P value <0.0001*
CD5+, % Spearman’s rho -0.199
P value 0.291
TNFα+, % Spearman’s rho
P value
IL6+, % Spearman’s rho
P value
IL2+, % Spearman’s rho
P value
IFNγ+, % Spearman’s rho
P value
IFN interferon, IL interleukin, TNF tumor necrosis factor. *Statistically significant resuactive disease and those in remission, and it is not a
useful marker to predict relapses.
Soluble CD27 is a marker for both B cell and T cell
activation [29, 30]. Levels of sCD27 were significantly
increased in GPA compared to controls. In contrast to
CCL19, the concentration of serum sCD27 significantly
increased with active disease. The increased sCD27 may
be a reflection of lymphocyte activation in GPA, which
increases upon relapse. While not predictive for diseaseIL6+, % IL2+, % IFNγ+, % IL10+, %
-0.063 0.586* 0.576* 0.053
0.702 <0.0001* 0.0001* 0.747
-0.292 -0.364* -0.168 0.049
0.071 0.023* 0.308 0.768
-0.115 0.553* 0.467* 0.043
0.487 <0.001* 0.003* 0.797
0.021 -0.132 -0.214 0.047
0.914 0.488 0.257 0.804
-0.012 0.733* 0.663* 0.237








Fig. 5 Serum CCL19 and sCD27 levels in (relapsing) patients with granulomatosis with polyangiitis (GPA) and controls. Serum levels of CCL19 and
sCD27 were determined by ELISA. a, b Patients in remission and with active disease were compared to healthy controls. c, d Patients in remission
were divided into those who relapsed soon after the sampling (future relapse) and those that did not relapse for at least 1.5 years (no future relapse). In
the box and whisker plots (Tukey), boxes represent the median values and interquartile range. e, f The relapsing patients were compared for two
consecutive time points in remission and the ensuing active disease time point. Each line represents an individual patient. *P < 0.05, ***p < 0.001
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disease. Another explanation for increased sCD27 is
increased shedding of the receptor. Surface CD27 can be
cleaved through the action of matrix metalloproteinases
(MMPs) [31]. As patients with active GPA have upregu-
lation of several MMPs [32] this could explain the in-
creased sCD27 in samples from patients with active
disease. Moreover, the presence of CD27-negative mem-
ory B cells has been described and it has been speculated
that the CD27-negative memory compartment contains
autoreactive B cells that have downregulated their acti-
vation molecules in an attempt to limit autoreactivity
[33]. While these cells are scarce in healthy individuals,
they are significantly increased in patients with systemic
lupus erythematosus (SLE) [34], and serum levels of
sCD27 are also increased in SLE patients compared to
controls [35]. The CD27-negative B cells could be a
source of sCD27 present in the serum; however, as T cells
can also express CD27 it is not the only possible source.
With regard to the Breg cytokine IL10, there were no
differences between controls and (relapsing) patients in
the total percentages of IL10-producing B cells. This
result is in line with our previous observations, which
showed a similar capacity for IL10 production by B cells
in AAV patients and controls [14]. However, there was a
significant decrease in IL10 production in individual
patients approaching a relapse, which was not seen in
patients in remission, indicating that B cell regulatory
capacity may decrease in individual patients prior to re-
lapse. Further investigation is warranted to fully confirm
these changes.The production of IL10 did not correlate with any of the
proposed surface marker phenotypes for Bregs. However,
none of these phenotypes have been fully confirmed as
clear Breg populations. Moreover, the stimulation with
CpG for 3 days may affect the phenotype of B cells in cul-
ture, resulting in a different subset distribution. For one,
CpG has been reported to induce naive B cell proliferation
without causing maturation into memory cells [36], and it
can prolong the lifespan of mature-naive B cells
in vitro [37]. Such changes could help explain the
lack of correlation between a phenotype analysis in
the peripheral blood and cytokine expression after
CpG stimulation, although one study has shown that
66 h stimulation with CpG does not significantly
affect the B cell subset distribution [38]. Regardless,
additional phenotypical analysis post CpG stimulation
may give a clearer picture of which B cells are re-
sponsible for the production of IL10 in this setting.
IL10 production did correlate with the production of
IL6 in Toll-like receptor (TLR)9-activated B cells, even
though IL6 is generally regarded as a proinflammatory
cytokine, and its overproduction has been related to the
onset of autoimmunity [39]. Moreover, blockade of the
IL6 receptor has proven to be an effective therapeutic
target in several autoimmune diseases, including RA
[40] and giant cell arteritis [41]. Marginal zone B cells
that produced high levels of IL6 in response to TLR4
stimulation simultaneously produced increased levels of
IL10 [7]. These cytokines can be separated, for example,
calcineurin antagonists have been demonstrated to se-
lectively inhibit IL10 release without affecting secretion
Land et al. Arthritis Research & Therapy  (2016) 18:84 Page 10 of 11of IL6 in TLR9-stimulated B cells [42]. In addition, we
demonstrated here that B cells can produce IL10 and TNFα
concomitantly, which has been described previously, with
CD24highCD27+ B cells having the largest fraction of
TNFα/IL10 dual positivity [43]. The capacity of certain B
cells to demonstrate both regulator and effector roles indi-
cates that the in vivo context is crucial in determining the B
cell function. While we demonstrated here that patients
with GPA and healthy individuals have a similar capacity
for B cell IL10 production after TLR9 activation, differences
in the in vivo environment could result in different B cell
cytokine production profiles.
There are limitations to our study, mainly due to the
restricted number of subjects that could be included.
Statistical analyses have not been corrected for multiple
testing, and we lacked sufficient power to correct for
multiple potential confounding factors. However, it was
clear that current immunosuppressive treatment was not
the underlying cause for the differences between patients
and controls. Furthermore, total B cell cytokine produc-
tion was determined here; it would be interesting to sort
specific B cell subsets, for example, memory B cells, and
determine cytokine production. Finally, results deter-
mined from peripheral samples may not be representa-
tive of active disease sites; however, biopsy studies will
not lead to biomarkers that are easy to measure.
Conclusions
Patients with GPA have a decreased percentage of
TNFα-producing B cells compared to controls. This
appears to be most prominent in those patients who are
about to relapse. However, effector B cell cytokine
production was not significantly different between re-
lapsing and non-relapsing patients, and could not clearly
differentiate which patients were about to relapse. IL10
production by B cells did decrease before relapse, and
monitoring this may have potential for relapse prediction.
Production of the effector cytokines TNFα, IL2, and IFNγ
by B cells is highly correlated with the presence of CD27+
B memory cells in the circulation. Increased CCL19 levels
suggest greater B cell migration in GPA, which may par-
ticularly affect memory B cells. The resulting changes in
the B cell subset distribution in GPA are likely responsible
for the aberrant proinflammatory cytokine production.
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